Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities
Bioorganic Chemistry · 2024-01 · 142 · 106934
DOI: 10.1016/j.bioorg.2023.106934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2024-01. Verfasst von Xia-Wen Dang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Elemene Class Anticancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditiona…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 148 Literaturangaben.
Abstract (Originalsprache)
Proto-oncogene tyrosine-protein kinase Src, also known as c-Src, belongs to the family of non-receptor tyrosine protein kinases (TKs) called Src kinases. It plays a crucial role in cell division, motility, adhesion, and survival in both normal cells and cancer cells by activating various signaling pathways mediated by multiple cytokines. Additionally, c-Src kinase has been implicated in osteoclasts and bone loss diseases mediated by inflammation and osteoporosis. In recent years, remarkable advancements have been achieved in the development of c-Src inhibitors, with several candidates progressing to the clinical stage. This review focuses on the research progress in several areas, including the mechanism of action, drug discovery, combination therapy, and clinical research. By presenting this information, we aim to provide researchers with convenient access to valuable insights and inspire new ideas to expedite future drug discovery programs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Key Laboratory of Elemene Class Anticancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Ch…
- Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA.
- College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
- Drug Discovery, Hangzhou HealZen Therapeutics Co., Ltd., Hangzhou, Zhejiang 310018, China. Electronic address: zhouxl@healZentx.com.
Zitieren
APA
Dang, X. W., Duan, J. L., Ye, E., Mao, N. D., Bai, R., Zhou, X., & Ye, X. Y. (2024). Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities. Bioorganic Chemistry, 142, 106934. https://doi.org/10.1016/j.bioorg.2023.106934
Vancouver
Dang XW, Duan JL, Ye E, Mao ND, Bai R, Zhou X, et al. Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities. Bioorganic Chemistry. 2024;142:106934. doi:10.1016/j.bioorg.2023.106934
BibTeX
@article{Dang2024,
author = {Dang, Xia-Wen and Duan, Ji-Long and Ye, Emily and Mao, Nian-Dong and Bai, RenRen and Zhou, Xinglu and Ye, Xiang-Yang},
title = {Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities},
journal = {Bioorganic Chemistry},
year = {2024},
volume = {142},
pages = {106934},
doi = {10.1016/j.bioorg.2023.106934}
}
EUVIMED